ERAS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.108

-1.4%

-0.107

-3.03%

-0.110

-8.33%

Estimates Revision

Stock Price

Go Up

+180.50%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

1.00

Averages

4.50

High

6.00

Current: 0.000

Low

1.00

Averages

4.50

High

6.00

Morgan Stanley

Equal Weight

maintain

$2 -> $4

2026-01-08

New

Reason

Morgan Stanley

Price Target

$2 -> $4

2026-01-08

New

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Erasca to $4 from $2 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Piper Sandler

Overweight

initiated

2026-01-07

New

Reason

Piper Sandler

Price Target

2026-01-07

New

initiated

Overweight

Reason

Piper Sandler initiated coverage of Erasca with an Overweight rating and $5 price target. The company is is advancing a "potentially differentiated" RAS-targeted pipeline including a pan-RAS molecular glue, and a pan- KRAS inhibitor, the analyst tells investors in a research note. The firm says preclinical data suggests the potential for superior RAS inhibition and anti-tumor activity virus Revolution Medicines' daraxonrasib.

BofA

Underperform

maintain

$1 -> $2

2026-01-06

New

Reason

BofA

Price Target

$1 -> $2

2026-01-06

New

maintain

Underperform

Reason

BofA raised the firm's price target on Erasca to $2 from $1 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Mizuho

Outperform

upgrade

$4 -> $5

2025-12-09

Reason

Mizuho

Price Target

$4 -> $5

2025-12-09

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Erasca to $5 from $4 and keeps an Outperform rating on the shares. The firm is "increasingly encouraged and constructive" on the RAS space and is bullish on Erasca ahead of its first U.S. Phase 1 clinical data for its two lead assets, ERAS-0015 and ERAS-4001. Mizuho sees large addressable markets for both candidates and notes that data is expected in 2026. The analyst sees an attractive risk/reward at current share levels.

Guggenheim

Buy

maintain

$3 -> $5

2025-11-14

Reason

Guggenheim

Price Target

$3 -> $5

2025-11-14

maintain

Buy

Reason

Guggenheim raised the firm's price target on Erasca to $5 from $3 and keeps a Buy rating on the shares after the company reported Q3 results and provided a pipeline update. The firm's raised target reflects recent Phase 1 trial initiations, recent additional validation from peer programs, and likely increasing investor anticipation ahead of the first potential clinical data disclosures from both of the company's programs in 2025, the analyst noted.

Stifel

Buy

maintain

$4 -> $6

2025-11-06

Reason

Stifel

Price Target

$4 -> $6

2025-11-06

maintain

Buy

Reason

Stifel raised the firm's price target on Erasca (ERAS) to $6 from $4 and keeps a Buy rating on the shares. The firm notes the company announced issuance of composition of matter patent for lead pan-RAS program ERAS-0015. Stifel views this as a significant de-risking event. The firm notes that no large pharma company, to its knowledge, has brought forward a pan-RAS molecular glue even in the wake of Revolution Medicines' (RVMD) pan-RAS dominance.

Valuation Metrics

The current forward P/E ratio for Erasca Inc (ERAS.O) is -8.13, compared to its 5-year average forward P/E of -4.84. For a more detailed relative valuation and DCF analysis to assess Erasca Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.84

Current PE

-8.13

Overvalued PE

-2.39

Undervalued PE

-7.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.80

Current EV/EBITDA

-4.36

Overvalued EV/EBITDA

0.88

Undervalued EV/EBITDA

-6.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ERAS News & Events

Events Timeline

No data

News

5.0

01-08Benzinga

Erasca Inc. Shares Surge Nearly 60% on Acquisition Rumors

6.0

01-08NASDAQ.COM

Erasca Inc (ERAS) Stock Surpasses Analyst Target Price of $4.12

9.5

01-08Benzinga

AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%

People Also Watch

Frequently Asked Questions

What is Erasca Inc (ERAS) stock price today?

The current price of ERAS is 6.76 USD — it has increased 16.35 % in the last trading day.

What is Erasca Inc (ERAS)'s business?

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

What is the price predicton of ERAS Stock?

What is Erasca Inc (ERAS)'s revenue for the last quarter?

Erasca Inc revenue for the last quarter amounts to -32.55M USD, decreased -12.61 % YoY.

What is Erasca Inc (ERAS)'s earnings per share (EPS) for the last quarter?

Erasca Inc. EPS for the last quarter amounts to -21664000.00 USD, decreased -3.39 % YoY.

What changes have occurred in the market's expectations for Erasca Inc (ERAS)'s fundamentals?

The market is revising No Change the revenue expectations for ERAS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 180.50%.

How many employees does Erasca Inc (ERAS). have?

Erasca Inc (ERAS) has 103 emplpoyees as of January 10 2026.

What is Erasca Inc (ERAS) market cap?

Today ERAS has the market capitalization of 1.65B USD.